IL7R and acute lymphoblastic leukemia: Taking into account that 10% of T-ALL patients carry IL-7Rα mutations that have been linked to poor prognosis and risk in relapsed patients, IL-7Rα and its signaling pathways have emerged as logical therapeutic targets (55).